Deirdre P Cronin-Fenton1, Anders Kjærsgaard1, Thomas P Ahern2, Marco Mele3, Marianne Ewertz4,5, Stephen Hamilton-Dutoit6, Peer M Christiansen3,7,8, Bent Ejlertsen8,9, Henrik T Sørensen1,10, Timothy L Lash1,11, Rebecca A Silliman1,12. 1. a Department of Clinical Epidemiology , Aarhus University Hospital , Aarhus , Denmark. 2. b The Robert Larner , M.D. College of Medicine at The University of Vermont , Burlington , VT , USA. 3. c Breast Unit, Surgical Department , Randers Regional Hospital , Randers , Denmark. 4. d Department of Oncology , Odense University Hospital , Odense , Denmark. 5. e Institute of Clinical Research , University of Southern Denmark , Odense , Denmark. 6. f Institute of Pathology , Aarhus University Hospital , Aarhus , Denmark. 7. g Department of Plastic and Breast Surgery , Aarhus University Hospital , Aarhus , Denmark. 8. h Danish Breast Cancer Cooperative Group , Copenhagen , Denmark. 9. i Rigshospitalet , Copenhagen , Denmark. 10. j Department of Health Research & Policy (Epidemiology) , Stanford University , Stanford , CA , USA. 11. k Department of Epidemiology, Rollins School of Public Health , Emory University , Atlanta , GA , USA. 12. l Boston University School of Medicine, Boston University , Boston , MA , USA.
Abstract
BACKGROUND: Validation studies of the Danish Breast Cancer Group (DBCG) registry show good agreement with medical records for adjuvant treatment data, but inconsistent recurrence information. No studies have validated changes in menopausal status or endocrine therapy during follow-up. In a longitudinal study, we validated DBCG data using medical records as the gold standard. MATERIAL AND METHODS: From a cohort of 5959 premenopausal women diagnosed during 2002-2010 with stage I-III breast cancer, we selected 151 patients - 77 estrogen-receptor-positive and 74 estrogen-receptor-negative - from three hospitals. We assessed the validity of DBCG registry data on patient, tumor, and treatment factors, and follow-up information on menopausal transition, changes in endocrine therapy, and recurrence. We computed positive predictive values (PPVs) with 95% confidence intervals (95%CI). RESULTS: Agreement was near perfect for tumor size, lymph node involvement, receptor status, surgery type, and receipt of radiotherapy, chemotherapy, or tamoxifen treatment. The PPV for a change in endocrine therapy in the DBCG was 96% (95%CI = 83, 100). The PPV for menopausal transition was 61% (95%CI = 42, 77). The PPV for DBCG-recorded recurrence was 100%. However, of 19 patients who had a recurrence documented in their medical record, 13 had the recurrence registered in DBCG. CONCLUSIONS: DBCG data are valid for most epidemiological studies of breast cancer treatment. Data on menopausal transition may be less valid, though this interpretation depends on the suitability of medical records for making this assessment. Although recurrence is missing for some, this would not bias most ratio measures of association.
BACKGROUND: Validation studies of the Danish Breast Cancer Group (DBCG) registry show good agreement with medical records for adjuvant treatment data, but inconsistent recurrence information. No studies have validated changes in menopausal status or endocrine therapy during follow-up. In a longitudinal study, we validated DBCG data using medical records as the gold standard. MATERIAL AND METHODS: From a cohort of 5959 premenopausal women diagnosed during 2002-2010 with stage I-III breast cancer, we selected 151 patients - 77 estrogen-receptor-positive and 74 estrogen-receptor-negative - from three hospitals. We assessed the validity of DBCG registry data on patient, tumor, and treatment factors, and follow-up information on menopausal transition, changes in endocrine therapy, and recurrence. We computed positive predictive values (PPVs) with 95% confidence intervals (95%CI). RESULTS: Agreement was near perfect for tumor size, lymph node involvement, receptor status, surgery type, and receipt of radiotherapy, chemotherapy, or tamoxifen treatment. The PPV for a change in endocrine therapy in the DBCG was 96% (95%CI = 83, 100). The PPV for menopausal transition was 61% (95%CI = 42, 77). The PPV for DBCG-recorded recurrence was 100%. However, of 19 patients who had a recurrence documented in their medical record, 13 had the recurrence registered in DBCG. CONCLUSIONS:DBCG data are valid for most epidemiological studies of breast cancer treatment. Data on menopausal transition may be less valid, though this interpretation depends on the suitability of medical records for making this assessment. Although recurrence is missing for some, this would not bias most ratio measures of association.
Authors: Thomas P Ahern; Per Damkier; Søren Feddersen; Anders Kjærsgaard; Timothy L Lash; Stephen Hamilton-Dutoit; Cathrine Bredal Lythjohan; Bent Ejlertsen; Peer M Christiansen; Deirdre P Cronin-Fenton Journal: Acta Oncol Date: 2020-04-30 Impact factor: 4.089
Authors: Cathrine F Hjorth; Per Damkier; Tore B Stage; Søren Feddersen; Stephen Hamilton-Dutoit; Mikael Rørth; Bent Ejlertsen; Timothy L Lash; Thomas P Ahern; Henrik T Sørensen; Deirdre Cronin-Fenton Journal: Breast Cancer Res Treat Date: 2022-04-30 Impact factor: 4.624
Authors: Lindsay J Collin; Deirdre P Cronin-Fenton; Thomas P Ahern; Peer M Christiansen; Per Damkier; Bent Ejlertsen; Stephen Hamilton-Dutoit; Anders Kjærsgaard; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash Journal: BMJ Open Date: 2018-08-01 Impact factor: 2.692
Authors: Sixten Harborg; Uffe Heide-Jørgensen; Thomas P Ahern; Marianne Ewertz; Deirdre Cronin-Fenton; Signe Borgquist Journal: Breast Cancer Res Treat Date: 2020-06-22 Impact factor: 4.872
Authors: Michael Rose; Henry Svensson; Jürgen Handler; Ute Hoyer; Anita Ringberg; Jonas Manjer Journal: Breast Cancer Res Treat Date: 2020-01-27 Impact factor: 4.872
Authors: Lindsay J Collin; Richard F MacLehose; Thomas P Ahern; Rebecca Nash; Darios Getahun; Douglas Roblin; Michael J Silverberg; Michael Goodman; Timothy L Lash Journal: Epidemiology Date: 2020-07 Impact factor: 4.860